Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Roche Holding (SWX:ROG) experienced a 14% increase in share price over the last quarter, driven in part by several key ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Level-1 evidence is usually obtained from high-powered, prospective and controlled studies, designed to test the role of a ... focus on measurement of HER-2/neu expression and its prognostic ...

Carcinomas arising in double transgenic Her2-neu/HeyL mice showed higher tumor vessel density and significantly faster ... Significance between different groups studied for angiogenesis was calculated ...

In addition, the basal expression of HER-2/neu offers an intrinsic control to calibrate the assay (2 copies/nucleus). The use of fluorescent dyes, however, restricts use of FISH to laboratories ...

No description, website, or topics provided.